Estrogen receptor
Estrogen receptor, abbreviated ER, is a common immunostain.
General
In the context of breast pathology it is a class II IHC test, as it is used for treatment decisions by itself.[1]
Positive
- Breast carcinoma - most.
- Ductal carcinoma in situ - most.
- Invasive lobular carcinoma - all.
- Invasive ductal carcinoma of the breast - most.
- Endometrial carcinomas.
Occasionally positive
- Lung adenocarcinoma - dependent on the ER subunit target - ERα ~1%, ERβ ~79%.[2]
Negative
See also
References
- ↑ Torlakovic, EE.; Riddell, R.; Banerjee, D.; El-Zimaity, H.; Pilavdzic, D.; Dawe, P.; Magliocco, A.; Barnes, P. et al. (Mar 2010). "Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.". Am J Clin Pathol 133 (3): 354-65. doi:10.1309/AJCPDYZ1XMF4HJWK. PMID 20154273.
- ↑ Tanaka, K.; Shimizu, K.; Kakegawa, S.; Ohtaki, Y.; Nagashima, T.; Kaira, K.; Horiguchi, J.; Oyama, T. et al. (2016). "Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.". Am J Transl Res 8 (1): 81-97. PMID 27069542.